BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

  Results of a Phase II/III study showed that patients who were given Tafinlar plus Mekinist saw an overall response rate of 47% vs. 11% for those who received standard chemotherapy only.

  June 7, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Merck Predicts Over 80 Potential Oncology Approvals Through 2028

  Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting a potential of more than 80 new regulatory approvals in oncology through 2028.

  June 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Novartis Latest Target in Cyberattack Extortion Plot

  Novartis has fallen victim to a cyberattack. The Swiss pharma giant’s data was hijacked by a well-known online extortion ring dubbed Industrial Spy.

  June 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Seres Touts Strong Phase III Results Against Recurrent C. Difficile Infection

  Seres Therapeutics, Inc. announced that the company’s Phase III Ecospor IV study demonstrated a strong safety profile in addition to statistically significant positive results against C. difficile infection.

  June 7, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Code Bio Launches with $75M to Disrupt Gene Therapy Space

  Code Bio, a biotechnology company leading the way in targeted non-viral delivery of generic medicines, closed a $75 million Series A financing round on Tuesday.

  June 7, 2022

   · 

  2 min read

   · 

  Paolo Besabella
• 

  Drug Development

  CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

  CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.

  June 7, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Aslan, Yumanity, Editas, Janssen and More Team Up to Fight Disease

  Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.

  June 7, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Policy

  Novavax on the Verge as FDA Adcom Recommends COVID-19 Vaccine

  On Tuesday, the FDA’s Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention to recommend authorization of Novavax’s COVID-19 vaccine.

  June 7, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years

  Sernova shared positive Phase I/II data from an ongoing clinical study of its implantable Cell Pouch device that showed evidence of in vivo active insulin production.

  June 7, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  J&J, Emergent Accuse Each Other Of Violating COVID-19 Vaccine Deal

  Johnson & Johnson and Emergent BioSolutions are accusing each other of breaching their COVID-19 vaccine supply agreement.

  June 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN